SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 254 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,821,791 | -16.2% | 682,691 | -8.7% | 0.01% | -16.7% |
| Q2 2023 | $22,469,309 | -8.8% | 747,482 | +10.0% | 0.01% | -14.3% |
| Q1 2023 | $24,629,626 | +5.7% | 679,813 | +4.0% | 0.01% | 0.0% |
| Q4 2022 | $23,306,422 | +8.5% | 653,390 | +3.0% | 0.01% | 0.0% |
| Q3 2022 | $21,476,000 | +8.8% | 634,429 | -7.0% | 0.01% | +16.7% |
| Q2 2022 | $19,733,000 | -1.6% | 682,316 | +9.9% | 0.01% | +20.0% |
| Q1 2022 | $20,064,000 | -7.5% | 620,779 | -16.6% | 0.01% | 0.0% |
| Q4 2021 | $21,702,000 | -21.1% | 744,265 | -27.9% | 0.01% | -28.6% |
| Q3 2021 | $27,518,000 | +17.8% | 1,031,780 | +36.0% | 0.01% | +16.7% |
| Q2 2021 | $23,352,000 | +22.6% | 758,403 | +4.3% | 0.01% | +20.0% |
| Q1 2021 | $19,040,000 | -5.4% | 727,283 | -9.1% | 0.01% | -16.7% |
| Q4 2020 | $20,137,000 | +31.4% | 800,338 | +8.8% | 0.01% | +20.0% |
| Q3 2020 | $15,325,000 | -7.8% | 735,368 | +5.0% | 0.01% | -16.7% |
| Q2 2020 | $16,627,000 | +13.3% | 700,113 | -14.1% | 0.01% | 0.0% |
| Q1 2020 | $14,669,000 | -40.3% | 815,391 | -21.3% | 0.01% | -25.0% |
| Q4 2019 | $24,572,000 | +158.7% | 1,035,935 | +199.7% | 0.01% | +300.0% |
| Q3 2019 | $9,498,000 | -28.1% | 345,625 | -13.4% | 0.00% | -33.3% |
| Q2 2019 | $13,209,000 | -57.1% | 399,171 | -54.6% | 0.00% | -70.0% |
| Q1 2019 | $30,785,000 | -0.2% | 878,549 | -5.4% | 0.01% | -16.7% |
| Q4 2018 | $30,849,000 | -62.2% | 928,624 | -42.8% | 0.01% | -53.8% |
| Q3 2018 | $81,673,000 | -8.4% | 1,622,095 | +8.9% | 0.03% | -13.3% |
| Q2 2018 | $89,174,000 | +22.9% | 1,489,969 | -6.0% | 0.03% | +11.1% |
| Q1 2018 | $72,585,000 | +14.9% | 1,584,828 | -0.0% | 0.03% | +17.4% |
| Q4 2017 | $63,169,000 | -23.4% | 1,585,132 | -23.2% | 0.02% | -23.3% |
| Q3 2017 | $82,507,000 | -14.4% | 2,062,652 | -7.7% | 0.03% | 0.0% |
| Q2 2017 | $96,368,000 | +85.5% | 2,235,905 | +34.7% | 0.03% | +76.5% |
| Q1 2017 | $51,946,000 | +6.1% | 1,659,594 | -14.4% | 0.02% | +6.2% |
| Q4 2016 | $48,973,000 | +4.5% | 1,939,493 | +2.3% | 0.02% | 0.0% |
| Q3 2016 | $46,885,000 | +45.3% | 1,895,928 | +19.7% | 0.02% | +33.3% |
| Q2 2016 | $32,257,000 | +75.1% | 1,583,603 | +31.1% | 0.01% | +71.4% |
| Q1 2016 | $18,427,000 | -15.3% | 1,208,345 | -25.3% | 0.01% | -22.2% |
| Q4 2015 | $21,749,000 | -0.7% | 1,618,250 | +3.6% | 0.01% | 0.0% |
| Q3 2015 | $21,908,000 | -12.3% | 1,561,418 | +6.1% | 0.01% | -10.0% |
| Q2 2015 | $24,979,000 | – | 1,471,073 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |